Workflow
Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa's Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting
BDRXBiodexa Pharmaceuticals PLC(BDRX) Newsfilter·2024-05-21 12:30

May 21, 2024 Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa's Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting Overall 83% non-progression rate at 6 Months Statistically Significant decrease in overall mean polyp burden at 6 months (p=0.04) Biodexa Pharmaceuticals PLC, (NASDAQ:BDRX), an acquisition-focused clinical stage biopharmaceu ...